StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a sell rating to a hold rating in a research report released on Monday. A number of other equities research analysts also recently weighed in on the company. Raymond James lowered their price target on Blueprint Medicines from $115.00 to $85.00 and set a […]
EFG Asset Management Americas Corp. trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 5.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,927 shares of the biotechnology company’s stock after selling 357 shares during the period. EFG Asset Management Americas Corp.’s holdings in Blueprint Medicines were worth […]
StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a sell rating to a hold rating in a report published on Monday morning. Several other brokerages also recently issued reports on BPMC. SVB Securities reduced their price objective on Blueprint Medicines from $45.00 to $38.00 in a research note on Friday, February 24th. […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday. Other equities research analysts have also issued reports about the company. Morgan Stanley cut their target price on Blueprint Medicines from $75.00 to $50.00 and set […]
EQRx’s plan to upend the US drug price system with lower-cost treatments is over. On Monday, it announced a massive strategic reset, slashing its pipeline…